Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637715 | 0.89 | ROCK2 (0.88) | ROCK2ROCK1CCNE1CDK2MEN1 | |
| SCHEMBL16637609 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL16637773 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL16648332 | 0.81 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL21573536 | 0.81 | ROCK2 (0.68) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL21573606 | 0.80 | ROCK2 (0.65) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL16637613 | 0.79 | ROCK2 (0.49) | ROCK2ROCK1CCNE1CDK2MEN1 | |
| SCHEMBL18792339 | 0.76 | ROCK2 (0.60) | ROCK2ROCK1 | |
| SCHEMBL29674712 | 0.76 | ROCK2 (0.58) | ROCK2ROCK1ALDH1A1LMNAMAPT | |
| SCHEMBL16637704 | 0.76 | ROCK2 (0.65) | ROCK2ROCK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20160237095-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160237095-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160237095-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2016-08-18 | — | — | US | disclosed |
| EP-3055301-A1 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015054317-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237095-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CCNE1 3045/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885CCNE1 2963/4885 |
| US-10125144-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CCNE1 3045/4885 |
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CCNE1 2073/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885CCNE1 1876/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CCNE1 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.